View All Vaccines

PaxVax to Develop New Adenovirus 4/7 Vaccine

PaxVax aims to overhaul current Adenovirus 4/7 vaccine against leading cause of Acute Respiratory Distress

Adenovirus 4/7 Vaccine Candidate Overview

What is Adenovirus?

Adenoviruses are a family of DNA viruses that cause a wide range of illnesses and symptoms, ranging from sore throat and conjunctivitis to respiratory conditions such as acute respiratory disease (ARD), which is a debilitating febrile disease that frequently results in severe pneumonia, hospitalization, and occasionally, death. ARD is frequently seen in military recruit training facilities.

What Causes ARD?

The primary pathogen responsible for morbidity among US recruits in training has been shown to be adenovirus. Adenovirus type 4 and adenovirus type 7 are common causes of acute respiratory disease in recruits who have no prior immunity.

Adenoviruses are usually spread from an infected person to others through the following:

  • close personal contact, such as touching or shaking hands
  • the air by coughing and sneezing
  • touching an object or surface with adenoviruses on it, then touching your mouth, nose, or eyes before washing your hands

What are Adenovirus Symptoms?

Adenoviral infections can lead to a debilitating febrile illness that may result in severe pneumonia, hospitalization, and occasionally, death. Adenoviral infections can be spread from person to person by aerosols created by sneezing or coughing, but can also be transmitted by close personal contact.

Close living quarters, coupled with the physical stress of training, can place military recruits at high risk for ARD. Prior to the availability of the Adenovirus 4/7 vaccine, epidemics of ARD infections were frequent in all branches of the military.

Adenovirus serotypes 4 & 7 are leading causes of ARD. Adenoviral infections are seen as an important issue in all military recruit training facilities. Close living quarters and physical stress place military recruits at uniquely high risk for developing ARD. The civilian population as a whole is at low risk of developing this disease.

PaxVax’s Adenovirus 4/7 Vaccine Pipeline Product

PaxVax is collaborating with the US government to develop a new version of the Adenovirus 4/7 vaccine that is currently being used by the U.S. military. The goal of the program is to modernize the production process, develop a capsule form of the vaccine and manufacture the vaccine in the US. The candidate vaccine is in Phase 1 clinical trials.